Skip to main content

PFE

Stock
Health Care
Drug Manufacturers - General

Performance overview

PFE Price
Price Chart

Forward-looking statistics

Beta
0.32
Risk
24.81%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer and his cousin Charles F. Erhart.

Company info

SectorHealth Care
IndustryDrug Manufacturers - General
Employees86K
Market cap$162.0B

Fundamentals

Enterprise value$183.2B
Revenue$62.5B
Revenue per employee—
Profit margin12.62%
Debt to equity68.84

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$1.38
Dividend per share$1.72
Revenue per share$11.02
Avg trading volume (30 day)$897M
Avg trading volume (10 day)$925M
Put-call ratio—

Macro factor sensitivity

Growth-1.0
Credit+2.8
Liquidity+0.3
Inflation-2.6
Commodities-0.3
Interest Rates-0.7

Valuation

Dividend yield6.75%
PEG Ratio8.66
Price to sales2.31
P/E Ratio8.66
Enterprise Value to Revenue2.93
Price to book1.60

Upcoming events

Next earnings dayApril 29, 2025
Next dividend day—
Ex. dividend dayJuly 25, 2025

News

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga (July 21, 2025)
Trade Tracker: Josh Brown Sells Pfizer

Josh Brown, CEO of Ritholtz Wealth Management, joins CNBC's "Halftime Report" to explain why he's selling Pfizer here.

CNBC Television (July 17, 2025)
Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.

CNBC (July 17, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free